安永受邀出席第十届医药创新与投资大会

Core Insights - The 10th Pharmaceutical Innovation and Investment Conference was held in Nanjing, co-hosted by the China Pharmaceutical Innovation Promotion Association and the Hong Kong Stock Exchange, focusing on opportunities and trends in China's pharmaceutical industry [2] - Ernst & Young has participated in this conference for the seventh time since 2018, co-hosting the Capital Market Forum, which discussed key topics such as the development trends in the healthcare industry and the dynamics of domestic and international listings [2][5] - The forum featured discussions on the challenges and opportunities for unprofitable innovative pharmaceutical companies following the reintroduction of the fifth set of standards for the Sci-Tech Innovation Board [5][6] Group 1: Capital Market Forum - The forum provided a platform for policy interpretation, experience sharing, and resource connection among participants from various sectors [2] - Discussions included the financing paths for unprofitable biotech companies and strategies for capturing market opportunities while enhancing internal capabilities [5] - Participants emphasized the importance of solid clinical data to achieve better performance in the capital market [6] Group 2: Tax and Regulatory Considerations - Tax regulatory scrutiny on large cross-border transactions in biotech firms has increased, prompting recommendations for early-stage global intellectual property arrangements to alleviate tax burdens [8] - Companies are advised to consider the implications of different accounting standards and listing rules when preparing for overseas listings, particularly in Hong Kong [10][12] Group 3: Financial Preparation for Listings - Financial preparation is critical for companies transitioning from A-share to Hong Kong listings, with a focus on ensuring consistency in financial disclosures [12] - The listing process is described as a comprehensive undertaking that requires meticulous planning across financial, legal, and operational aspects [12]